Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia

References

• Breems DA, Van Putten WLJ, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukaemia in first relapse. J Clin Oncol 2005;23:1969–1978.
   PubMed Web of Science ®Google Scholar
• Fiegl M, Unterhalt M, Kern W, et al. Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukaemia: a randomized trial of the AMLCG. Leukemia 2014;28:1001–1007.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Gardin C, Gachard N, et al. Outcome of older patients with acute myeloid leukaemia in first relapse. Am J Hematol 2013;88:758–764.
   PubMed Web of Science ®Google Scholar
• van Der Velden VH, Marvelde te JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukaemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001;97:3197–3204.
   PubMed Web of Science ®Google Scholar
• Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukaemia in first recurrence. Cancer 2005;104:1442–1452.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Delaunay J, Turlure P, et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukaemia. J Clin Oncol 2008;26:5192–5197.
   PubMed Web of Science ®Google Scholar
• Stone RM, Moser B, Sanford B, et al. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukaemia: Cancer and Leukaemia Group B study 19902. Leuk Res 2011;35:329–333.
   PubMed Web of Science ®Google Scholar
• Brethon B, Yakouben K, Oudot C, et al. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol 2008;143:541–547.
   PubMed Web of Science ®Google Scholar
• Specchia G, Pastore D, Carluccio P, et al. Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukaemia patients: a single-centre experience. Ann Hematol 2007;86:425–428.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Martinelli G, Rondoni M, et al. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 2004;28:987–990.
   PubMed Web of Science ®Google Scholar
• Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukaemia. Cancer Chemother Pharmacol 2003;51:87–90.
   PubMed Web of Science ®Google Scholar
• Apostolidou E, Cortes J, Tsimberidou A, et al. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukaemia. Leuk Res 2003;27:887–891.
   PubMed Web of Science ®Google Scholar
• Tsimberidou A, Cortes J, Thomas D, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33 + primary resistant or relapsed acute myeloid leukaemia. Leuk Res 2003;27:893–897.
   PubMed Web of Science ®Google Scholar
• Cortes J, Tsimberidou AM, Alvarez R, et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukaemia. Cancer Chemother Pharmacol 2002;50: 497–500.
   PubMed Web of Science ®Google Scholar
• Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. J. Clin Oncol 2001;19:3244–3254.
   PubMed Web of Science ®Google Scholar
• Filanovsky K, Shvidel L, Shtalrid M. Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukaemia. J Clin Oncol 2010;28:e115–e116; author reply e117–e118.
   PubMed Web of Science ®Google Scholar
• Fianchi L, Pagano L, Leoni F, et al. Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukaemia. Ann Oncol 2008;19:128–134.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Garcia-Manero G, Cortes J, et al. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukaemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukaemia. Clin Lymphoma Myeloma Leuk 2012;12:244–251.
   PubMed Web of Science ®Google Scholar
• Taksin A-L, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukaemia: a prospective study of the alfa group. Leukemia 2007;21:66–71.
   PubMed Web of Science ®Google Scholar
• Farhat H, Reman O, Raffoux E, et al. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukaemia salvage in patients aged 50–70-year old: a phase study of the acute leukaemia French association. Am J Hematol 2012;87:62–65.
   PubMed Web of Science ®Google Scholar
• Prebet T, Etienne A, Devillier R, et al. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukaemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study. Cancer 2011;117:974–981.
   PubMed Web of Science ®Google Scholar
• Pilorge S, Rigaudeau S, Rabian F, et al. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukaemia in late first relapse. Am J Hematol 2014;89:399–403.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:1508–1516.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukaemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Patel S, Ho M, et al. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukaemia: a single-centre experience. Am J Hematol 2010;85:877–881.
   PubMed Web of Science ®Google Scholar
• Trifilio S, Zhou Z, Altman J, et al. Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukaemia. Leuk Res 2013;37:872–876.
   PubMed Web of Science ®Google Scholar
• Fong CY, Grigoriadis G, Hocking J, et al. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukaemia at first relapse. Leuk Lymphoma 2013;54:336–341.
   PubMed Web of Science ®Google Scholar
• Lee ST, Jang JH, Suh HC, et al. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukaemia and high-risk myelodysplastic syndrome. Am J Hematol 2001;68:237–245.
   PubMed Web of Science ®Google Scholar
• Martin MG, Augustin KM, Uy GL, et al. Salvage therapy for acute myeloid leukaemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. Am J Hematol 2009;84:733–737.
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Leblond V, Michallet M, et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukaemia. Blood 1991;77:1894–1900.
   PubMed Web of Science ®Google Scholar